Search for content, post, videos

Sobi, Exelixis Extend Agreement

Swedish Orphan Biovitrum AB (Sobi) has restructured and extended an agreement with Exelixis, Inc. to December 31, 2019. Sobi is responsible for the commercialization and distribution of Cometriq® (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia and Turkey. The collaboration originated in February 2013, and was scheduled to expire December 31, 2015.